ImmunologyJournal of VirologyPeer-reviewed
Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearance
Tin Phan, Ruy Miguel Ribeiro, Gregory E. Edelstein…·Alan S. Perelson
The paper models viral rebound after nirmatrelvir-ritonavir treatment, finding that target cell preservation and incomplete viral clearance drive rebound, with extended treatment reducing this risk.
21 citationstop 1%